%0 Journal Article %T Multi-Compartment SCFA Quantification in Human %A Jé %A ré %A my Monteiro %A Antoine Lefè %A vre %A Diane Dufour-Rainfray %A Adeline Oury %A Gabrielle Chicheri %A Laurent Galineau %A Hé %A lè %A ne Blasco %A Lydie Nadal-Desbarats %A Patrick Emond %J American Journal of Analytical Chemistry %P 177-200 %@ 2156-8278 %D 2024 %I Scientific Research Publishing %R 10.4236/ajac.2024.156012 %X Short-chain fatty acids (SCFA) play an important role in human biochemistry. They originate primarily from the digestive system through carbohydrates microbial fermentation. Most SCFA produced in the colon are absorbed by the intestinal wall and enter the bloodstream to be distributed throughout the body for multiple purposes. At the intestinal level, SCFA play a role in controlling fat storage and fatty acid metabolism. The effects of these beneficial compounds therefore concern overall health. They facilitate energy expenditure and are valuable allies in the fight against obesity and diabetes. SCFA are also involved in the regulation of the levels of several neurotransmitters such as GABA (γ-aminobutyric acid), glutamate, serotonin, dopamine, and norepinephrine. Their role is also highlighted in many inflammatory and neurodegenerative diseases such as Alzheimer’s disease (AD) or Parkinson’s disease (PD). To have a realistic picture of the distribution of SCFA in different biological compartments of the human body, we propose to study SCFA simultaneously in five human biological samples: feces, saliva, serum, cerebrospinal fluid (CSF), and urine, as well as in Dried Blood Spot (DBS). To evaluate their concentration and repeatability, we used 10 aliquots from pooled samples, analyzed by 3-nitrophenylhydrazine (3-NPH) derivation and liquid chromatography coupled with high sensitivity mass spectrometry (LC-QqQ-MS). We also evaluated the SCFA assay on Dried Blood Spot (DBS). In this work, we adapted the pre-analytical parts for each sample to be able to use a common calibration curve, thus facilitating multi-assay quantification studies and so being less time-consuming. Moreover, we proposed new daughter ions from the same neutral loss (43 Da) to quantify SCFAs, thus improving the sensitivity. In conclusion, our methodology, based on a unique calibration curve for all samples for each SCFA, is well-suited to quantified them in a clinical context. %K LC-MS %K 3-Nitrophenylhydrazine %K Short-Chain Fatty Acids %K Human Biological Samples %K Quantification %U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=133988